These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17971813)

  • 1. Translational research on vaccines: influenza as an example.
    Belshe RB
    Clin Pharmacol Ther; 2007 Dec; 82(6):745-9. PubMed ID: 17971813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccines: recent advances in production technologies.
    Bardiya N; Bae JH
    Appl Microbiol Biotechnol; 2005 May; 67(3):299-305. PubMed ID: 15660212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine).
    Mabrouk T; Ellis RW
    Dev Biol (Basel); 2002; 110():125-34. PubMed ID: 12477315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vaccines for influenza virus.
    Tripp RA; Tompkins SM
    Curr Opin Investig Drugs; 2008 Aug; 9(8):836-45. PubMed ID: 18666031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined vaccines--the European contribution.
    Glück R
    Biologicals; 1994 Dec; 22(4):347-51. PubMed ID: 7779361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old and new vaccine approaches.
    Arnon R; Ben-Yedidia T
    Int Immunopharmacol; 2003 Aug; 3(8):1195-204. PubMed ID: 12860175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging data on the safety and efficacy of influenza vaccines in children.
    Vesikari T
    Pediatr Infect Dis J; 2008 Nov; 27(11 Suppl):S159-61. PubMed ID: 18955892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel recombinant influenza vaccine in insect cells.
    McPherson CE
    Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines.
    He XS; Holmes TH; Mahmood K; Kemble GW; Dekker CL; Arvin AM; Greenberg HB
    J Infect Dis; 2008 Mar; 197(6):803-11. PubMed ID: 18279048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.
    Hegde NR
    Hum Vaccin Immunother; 2015; 11(5):1223-34. PubMed ID: 25875691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.
    Fu TM; Grimm KM; Citron MP; Freed DC; Fan J; Keller PM; Shiver JW; Liang X; Joyce JG
    Vaccine; 2009 Feb; 27(9):1440-7. PubMed ID: 19146898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using plant cells as influenza vaccine substrates.
    Chichester JA; Haaheim LR; Yusibov V
    Expert Rev Vaccines; 2009 Apr; 8(4):493-8. PubMed ID: 19348564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.